Sotagliflozin, a dual SGLTI and SGLT2 inhibitor, can significantly reduce the risk of adverse cardiovascular events in patients with type 2 diabetes, CKD and additional cardiovascular risk factors, according to a new study of more than 10,000 patients. 

The median follow-up period was more than nine years, allowing researchers to compare long-term outcomes after both CABG and PCI. 

Researchers used advanced AI to see if any FDA-approved medications could potentially reverse one of the mutations behind dilated cardiomyopathy. Risedronate, a popular osteoporosis medication, is the one candidate that got the job done.

Johnson & Johnson MedTech has resumed the U.S. rollout of its Varipulse PFA system, sharing new warnings to help physicians. 

Military veterans face an increased risk of cardiovascular disease, making it especially important to ensure they receive high-quality care.

These findings show that opportunistic imaging could go a long way toward making more patients aware of the cardiovascular risks they face—all without requiring additional scans to be performed. 

It can be challenging to know which AFib patients are the best candidates for LAAO. A new algorithm out of Mayo Clinic aims to address that problem. 

No devices need to be returned at this time. However, the FDA warned, using these heart pumps without reviewing the updated instructions could result in "serious injury or death.” 

Other procedures are associated with higher profits—heart transplants, for instance—but CABG and TAVR are performed much more often.

A trio of leading voices in cardiology reviewed years of data while considering their proposal. The choice between TAVR and SAVR, they added, should be made on a case-by-case basis.